Eterna Therapeutics ERNA 深 滬
已收盤 05-08 16:00:00 美东时间
7.53
-0.290
-3.71%
華盛通- 最 高8.11
- 今 開7.74
- 成交量 145.87万股
- 最 低 6.3878
- 昨 收 7.82
- 總市值 878.13万
- 52周最高 93.75
- 市盈率 靜 --
- 換手率 125.08%
- 52周最低 3.1829
- 委 比 58.79%
- 總股本 116.62万
- 歷史最高 4762500.00
- 量 比 0.10
- 振 幅 22.02%
- 歷史最低 3.355
- 每 手 1
- 風險率 21.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Agilon Health (NYSE:AGL) shares moved upwards by 115.7% to $60.08 duri...
05-08 01:05
Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data
Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade.
05-06 22:52
Ernexa Therapeutics Announces 1-For-25 Reverse Stock Split Effective May 4
The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number for
04-30 21:02
Ernexa Therapeutics ERNA-101 Shows Durable Tumor Regression With PD-1 Blockade In Preclinical Ovarian Cancer Models; IND Submission Planned Q3 2026; First-In-Human Trial Expected Q4 2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancerIND submission for ERNA-101 expected in Q3 2026 with first-in-human
03-31 20:58
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
Why ZIM Integrated Shipping Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Shares of ZIM Integrated Shipping Services Ltd (NYSE:ZIM) rose sharply in pre-m...
02-17 17:21
Ernexa Therapeutics Prices Registered Public Offering Of 21M Shares And Warrants At $0.50 Per Share And Accompanying Warrant
Ernexa Therapeutics Inc. (NASDAQ:ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a
02-06 22:27
Ernexa Therapeutics Selected For Exclusive Japan Entry Acceleration Program, Advancing Cell Therapy Pipeline In Oncology and Autoimmune Disease
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies
01-27 21:48
Ernexa Therapeutics Completes Pre‑IND Meeting With FDA, Secures Pathway To IND And First‑In‑Human Ovarian Cancer Trial In H2 2026
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readinessCompany on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half
01-06 21:18
